Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- D-1 G Cdk-4 E-2F E2-F 6 GSK-3? GSK3-? CCND-1 RM-241
- Product Overview:
Cyclin D1 is a regulatory protein that controls cell proliferation by promoting cell cycle progression from G1 to S phase.{59540} It is induced during the G1 phase following stimulation with mitogens, including growth factors, hormones, and cytokines, and heterodimerizes with cyclin-dependent kinase 4 (Cdk4) or Cdk6 in the cytoplasm.{59541,59542} The cyclin D1/Cdk4/6 complex translocates to the nucleus and phosphorylates retinoblastoma protein (Rb), permitting expression of E2F transcription factors, which drive S phase entry and progression.{59542,59543,59540} During the G1/S phase transition, cyclin D1 is phosphorylated by glycogen synthase kinase 3? (GSK3?) and exported to the cytoplasm where it is ubiquitinated and degraded. CCND1, the gene encoding cyclin D1, is overexpressed in a variety of human cancers, including mantle cell lymphoma, pancreatic cancer, and breast cancer, and tumor cyclin D1 levels are increased in patients with colorectal cancer and associated with decreased overall survival.{59544,59545} Cayman’s Cyclin D1 Rabbit Monoclonal Antibody can be used for immunohistochemistry (IHC) and Western blot (WB) applications. The antibody recognizes cyclin D1 at approximately 34 kDa from human samples.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.